Investigational drug · Phase 3
pz-cel
Also called: EB-101 Surgical application of RDEB wounds
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "pz-cel"
First trial start
2023
Apr 2, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "pz-cel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
- RDEB
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "pz-cel" as an intervention, largest first.
- Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of WoundsNot yet recruiting
Abeona Therapeutics, IncIndustry
NCT07717736 · 100 participants (planned) · Start Nov 2026 · Primary completion Nov 2031
Drug: Non-conforming pz-cel surgical application to RDEB wounds; Pz-cel surgical application to DEB wounds · For: Epidermolysis Bullosa (EB); Recessive Dystrophic Epidermolysis Bullosa (RDEB); Dystrophic Epidermolysis Bullosa (DEB)
- A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEBEnrolling by invitation
Abeona Therapeutics, IncIndustry
NCT05708677 · 22 participants (planned) · Start Feb 9, 2021 · Primary completion Feb 2036
Drug: EB-101 · For: RDEB
Sites: Redwood City, California; Worcester, Massachusetts
- A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsPivotal-lookingActive, not recruiting
Abeona Therapeutics, IncIndustry
NCT05725018 · 12 participants (planned) · Start Apr 2, 2023 · Primary completion Sep 30, 2025
Drug: EB-101 Surgical application of RDEB wounds · For: Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB
Sites: Redwood City, California; Worcester, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
- Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa.
Pappalardo A, Eid E, Olsen RC, et al. · Pediatr Dermatol 2026
Also in development for Epidermolysis Bullosa
- allo-APZ2-OTSPhase 32 trials
RHEACELL GmbH & Co. KG · Epidermolysis Bullosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.